|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
Dobutamine results in decreased activity of ABCB11 protein |
CTD |
PMID:28437613 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Adcy6 |
adenylate cyclase 6 |
affects response to substance |
ISO |
ADCY6 protein affects the susceptibility to Dobutamine |
CTD |
PMID:12393090 |
|
NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
Dobutamine binds to and results in increased activity of ADRA2A protein |
CTD |
PMID:16024912 |
|
NCBI chr 1:274,766,283...274,769,083
Ensembl chr 1:274,766,283...274,769,081
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects response to substance multiple interactions |
ISO EXP |
ADRB1 gene affects the susceptibility to Dobutamine; ADRB1 gene polymorphism affects the susceptibility to Dobutamine; ADRB1 protein polymorphism affects the susceptibility to Dobutamine ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Oxygen deficiency results in increased susceptibility to [Dobutamine binds to and results in increased activity of ADRB1 protein] |
CTD |
PMID:8096834 PMID:10192281 PMID:11753577 PMID:14502278 PMID:15564877 PMID:16024912 PMID:18787115 PMID:19719783 PMID:20821015 PMID:21311897 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects response to substance |
ISO |
ADRB2 gene polymorphism affects the susceptibility to Dobutamine |
CTD |
PMID:17094270 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP |
[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein |
CTD |
PMID:19719783 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
affects response to substance |
ISO |
AHSG protein affects the susceptibility to Dobutamine |
CTD |
PMID:16177000 |
|
NCBI chr11:81,711,269...81,717,594
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects response to substance multiple interactions |
ISO EXP |
AKT1 protein affects the susceptibility to Dobutamine Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16094411 PMID:16339297 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 |
|
NCBI chr10:57,040,252...57,048,045
Ensembl chr10:57,040,267...57,048,134
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
Dobutamine results in increased expression of BAX protein |
CTD |
PMID:15052282 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Dobutamine results in decreased expression of BCL2 protein |
CTD |
PMID:15052282 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bnip1 |
BCL2 interacting protein 1 |
increases expression |
ISO |
Dobutamine results in increased expression of BNIP1 protein |
CTD |
PMID:15052282 |
|
NCBI chr10:16,677,077...16,689,321
Ensembl chr10:16,677,077...16,689,321
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:12818967 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein] |
CTD |
PMID:12818968 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Clu |
clusterin |
increases expression |
ISO |
Dobutamine results in increased expression of CLU protein |
CTD |
PMID:15052282 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Comt |
catechol-O-methyltransferase |
increases methylation increases expression |
ISO EXP |
COMT protein results in increased methylation of Dobutamine Dobutamine results in increased expression of COMT mRNA |
CTD |
PMID:11160877 PMID:12423672 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Dobutamine results in increased expression of CPT1A mRNA; Dobutamine results in increased expression of CPT1A protein |
CTD |
PMID:8479178 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crem |
cAMP responsive element modulator |
affects response to substance |
ISO |
CREM protein affects the susceptibility to Dobutamine |
CTD |
PMID:12475904 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Ctf1 |
cardiotrophin 1 |
affects response to substance |
ISO |
CTF1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:17150369 |
|
NCBI chr 1:199,162,319...199,168,296
Ensembl chr 1:199,163,086...199,168,296
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA] |
CTD |
PMID:11605937 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Dbh |
dopamine beta-hydroxylase |
affects response to substance |
ISO |
DBH protein affects the susceptibility to Dobutamine |
CTD |
PMID:10338466 |
|
NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
|
|
G |
Dmd |
dystrophin |
increases response to substance |
ISO |
DMD gene mutant form results in increased susceptibility to Dobutamine |
CTD |
PMID:17440445 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases response to substance multiple interactions |
ISO |
EGFR gene mutant form results in decreased susceptibility to Dobutamine AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18599591 PMID:18787115 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Dobutamine binds to and results in increased activity of ESR1 protein |
CTD |
PMID:24928891 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Dobutamine results in increased expression of F3 protein |
CTD |
PMID:16286589 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
affects response to substance |
ISO |
FGF2 protein affects the susceptibility to Dobutamine |
CTD |
PMID:10491406 PMID:14583313 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
Dobutamine results in increased activity of G6PD protein |
CTD |
PMID:1978808 |
|
NCBI chr X:156,274,800...156,293,935
Ensembl chr X:156,274,800...156,293,926
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein promotes the reaction [Dobutamine results in increased metabolism of Lipids] |
CTD |
PMID:14981226 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Gk |
glycerol kinase |
increases activity |
EXP |
Dobutamine results in increased activity of GK protein |
CTD |
PMID:12736183 |
|
NCBI chr X:54,227,291...54,303,897
Ensembl chr X:54,227,397...54,303,864
|
|
G |
Gnas |
GNAS complex locus |
increases response to substance |
ISO |
GNAS gene SNP results in increased susceptibility to Dobutamine |
CTD |
PMID:19542315 |
|
NCBI chr 3:172,374,957...172,434,988
Ensembl chr 3:172,374,957...172,428,483 Ensembl chr 3:172,374,957...172,428,483
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
affects response to substance |
ISO |
GSK3B gene mutant form affects the susceptibility to Dobutamine |
CTD |
PMID:17901358 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18787115 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP |
esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein] Dobutamine results in increased expression of HMOX1 mRNA; Dobutamine results in increased expression of HMOX1 protein |
CTD |
PMID:15179140 PMID:16627864 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases response to substance |
EXP |
IGF1 protein results in increased susceptibility to Dobutamine |
CTD |
PMID:17184500 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein] Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein] |
CTD |
PMID:11605937 PMID:15502056 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
Dobutamine results in increased expression of IL1B mRNA |
CTD |
PMID:9387890 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases expression decreases expression multiple interactions |
ISO EXP |
Dobutamine results in increased expression of IL6 protein Dobutamine results in decreased expression of IL6 mRNA Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] |
CTD |
PMID:11605937 PMID:12423672 PMID:16286589 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itgb1 |
integrin subunit beta 1 |
affects response to substance |
ISO |
ITGB1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:11884376 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr16:20,485,028...20,486,707
Ensembl chr16:20,485,029...20,486,707
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Dobutamine results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions affects response to substance |
ISO |
KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium] KCNJ11 protein affects the susceptibility to Dobutamine |
CTD |
PMID:17189350 |
|
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
|
|
G |
Klk1 |
kallikrein 1 |
affects response to substance |
ISO |
KLK1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:12411458 |
|
NCBI chr 1:100,131,562...100,135,556
Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329 Ensembl chr 1:100,059,967...100,203,329
|
|
G |
Lep |
leptin |
decreases secretion decreases expression |
ISO |
Dobutamine results in decreased secretion of LEP protein Dobutamine results in decreased expression of LEP mRNA; Dobutamine results in decreased expression of LEP protein |
CTD |
PMID:9002984 PMID:11022189 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR protein affects the susceptibility to Dobutamine |
CTD |
PMID:20175764 |
|
NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] Dobutamine results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:16760913 PMID:18787115 PMID:19719783 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] Dobutamine results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:16760913 PMID:18787115 PMID:19719783 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein |
CTD |
PMID:19719783 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mb |
myoglobin |
affects response to substance |
ISO |
MB protein affects the susceptibility to Dobutamine |
CTD |
PMID:10468637 |
|
NCBI chr 7:118,101,633...118,108,864
Ensembl chr 7:118,101,634...118,108,864
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein] |
CTD |
PMID:15502056 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nos1 |
nitric oxide synthase 1 |
affects response to substance |
ISO |
NOS1 protein affects the susceptibility to Dobutamine |
CTD |
PMID:16344403 |
|
NCBI chr12:44,214,949...44,405,530
Ensembl chr12:44,213,943...44,520,341
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects response to substance |
ISO |
NOS2 protein affects the susceptibility to Dobutamine |
CTD |
PMID:9396439 PMID:11489778 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases activity |
ISO |
Dobutamine results in increased activity of NR1H4 protein |
CTD |
PMID:22414727 |
|
NCBI chr 7:30,003,429...30,162,095
Ensembl chr 7:30,003,429...30,162,056
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases expression |
EXP |
Dobutamine results in increased expression of PHGDH mRNA |
CTD |
PMID:12423672 |
|
NCBI chr 2:200,484,245...200,513,564
Ensembl chr 2:200,484,246...200,513,564
|
|
G |
Pln |
phospholamban |
affects response to substance |
ISO |
PLN protein affects the susceptibility to Dobutamine |
CTD |
PMID:14991071 |
|
NCBI chr20:34,633,157...34,642,904
Ensembl chr20:34,633,157...34,642,904
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
affects response to substance |
ISO |
PPP2CA protein affects the susceptibility to Dobutamine |
CTD |
PMID:15247211 |
|
NCBI chr10:37,534,449...37,554,861
Ensembl chr10:37,535,871...37,554,664
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] |
CTD |
PMID:16339297 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkce |
protein kinase C, epsilon |
affects response to substance |
ISO |
PRKCE protein affects the susceptibility to Dobutamine |
CTD |
PMID:15242976 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prop1 |
PROP paired-like homeobox 1 |
decreases response to substance |
ISO |
PROP1 gene mutant form results in decreased susceptibility to Dobutamine |
CTD |
PMID:19414510 |
|
NCBI chr10:36,449,920...36,452,381
Ensembl chr10:36,449,920...36,452,378
|
|
G |
Ren |
renin |
multiple interactions increases expression increases secretion increases activity |
ISO |
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Dactinomycin inhibits the reaction [Dobutamine results in increased secretion of REN protein] Dobutamine results in increased expression of REN mRNA Dobutamine results in increased activity of REN protein |
CTD |
PMID:9203624 PMID:9209250 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
S100a1 |
S100 calcium binding protein A1 |
increases response to substance |
ISO |
S100A1 gene mutant form results in increased susceptibility to Dobutamine |
CTD |
PMID:18645228 |
|
NCBI chr 2:189,900,505...189,905,348
Ensembl chr 2:189,900,667...189,903,219
|
|
G |
Scnn1g |
sodium channel epithelial 1 subunit gamma |
increases expression |
EXP |
Dobutamine results in increased expression of SCNN1G mRNA |
CTD |
PMID:16638327 |
|
NCBI chr 1:191,704,397...191,738,271
Ensembl chr 1:191,704,311...191,738,268
|
|
G |
Sgcd |
sarcoglycan, delta |
affects response to substance |
ISO |
SGCD affects the susceptibility to Dobutamine |
CTD |
PMID:20675662 |
|
NCBI chr10:32,062,946...32,471,454
Ensembl chr10:32,062,946...32,471,454
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
increases degradation |
EXP |
Dobutamine deficiency results in increased degradation of SPTAN1 protein |
CTD |
PMID:15849228 |
|
NCBI chr 3:8,534,437...8,599,259
Ensembl chr 3:8,534,440...8,599,260
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
ISO |
Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein] |
CTD |
PMID:8994422 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
ISO |
Dobutamine promotes the reaction [TAC1 protein binds to and results in increased activity of TACR1 protein] |
CTD |
PMID:8994422 |
|
NCBI chr 4:113,247,236...113,416,139
Ensembl chr 4:113,247,795...113,414,504
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Dobutamine results in increased expression of TGFB1 mRNA |
CTD |
PMID:16760913 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression |
EXP |
Dobutamine results in increased expression of TGFB2 mRNA |
CTD |
PMID:16760913 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression decreases secretion |
EXP |
Dobutamine results in decreased expression of TNF mRNA Dobutamine results in decreased secretion of TNF protein |
CTD |
PMID:12423672 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [Dobutamine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Dobutamine results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:89,797,750...89,805,561
Ensembl chr13:89,797,800...89,805,558
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects response to substance |
ISO |
VEGFA protein affects the susceptibility to Dobutamine |
CTD |
PMID:11599061 PMID:14583313 PMID:19237429 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|